Fresh native human tissue slices in 96-well plate fomat compatible with phenotypic high content biology for drug screening and advanced target validation

Biopta sources fresh human tissue through ethical routes and uses them to study the action of potential new medicines. It performs these studies for drug companies and for and in collaboraton with academic and NHS partners. This provides an invaluable source of data to help understand and improve existing therapies. But Biopta can and wants to do more. The amount of information we an get from these tisssues can be increased if we miniturise the study conditions (tissue can go further) and if we apply them to the most up-to-date technical instruments e.g. high content analysis systems collects more biological data than conventional systems. Thus, we can get more imformation from the human tissue. This will increase the impact that fresh human tissue has on the discovery of new medicines.